rs115134980
Variant names:
Your query was ambiguous. Multiple possible variants found:
Variant summary
Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_000203.5(IDUA):c.1402+36T>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.162 in 1,392,176 control chromosomes in the GnomAD database, including 19,452 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.17 ( 2402 hom., cov: 33)
Exomes 𝑓: 0.16 ( 17050 hom. )
Consequence
IDUA
NM_000203.5 intron
NM_000203.5 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: -3.42
Genes affected
IDUA (HGNC:5391): (alpha-L-iduronidase) This gene encodes an enzyme that hydrolyzes the terminal alpha-L-iduronic acid residues of two glycosaminoglycans, dermatan sulfate and heparan sulfate. This hydrolysis is required for the lysosomal degradation of these glycosaminoglycans. Mutations in this gene that result in enzymatic deficiency lead to the autosomal recessive disease mucopolysaccharidosis type I (MPS I). [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.89).
BP6
Variant 4-1002980-T-C is Benign according to our data. Variant chr4-1002980-T-C is described in ClinVar as [Benign]. Clinvar id is 255522.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.288 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.175 AC: 26500AN: 151524Hom.: 2406 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
26500
AN:
151524
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.157 AC: 5479AN: 34990 AF XY: 0.169 show subpopulations
GnomAD2 exomes
AF:
AC:
5479
AN:
34990
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.160 AC: 199015AN: 1240546Hom.: 17050 Cov.: 36 AF XY: 0.163 AC XY: 98716AN XY: 605004 show subpopulations
GnomAD4 exome
AF:
AC:
199015
AN:
1240546
Hom.:
Cov.:
36
AF XY:
AC XY:
98716
AN XY:
605004
Gnomad4 AFR exome
AF:
AC:
5436
AN:
24710
Gnomad4 AMR exome
AF:
AC:
1316
AN:
14828
Gnomad4 ASJ exome
AF:
AC:
2973
AN:
18962
Gnomad4 EAS exome
AF:
AC:
4352
AN:
27658
Gnomad4 SAS exome
AF:
AC:
16925
AN:
58144
Gnomad4 FIN exome
AF:
AC:
5330
AN:
30434
Gnomad4 NFE exome
AF:
AC:
153171
AN:
1009998
Gnomad4 Remaining exome
AF:
AC:
8551
AN:
51022
Heterozygous variant carriers
0
9325
18650
27975
37300
46625
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Exome Het
Exome Hom
Variant carriers
0
5916
11832
17748
23664
29580
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.175 AC: 26496AN: 151630Hom.: 2402 Cov.: 33 AF XY: 0.176 AC XY: 13040AN XY: 74122 show subpopulations
GnomAD4 genome
AF:
AC:
26496
AN:
151630
Hom.:
Cov.:
33
AF XY:
AC XY:
13040
AN XY:
74122
Gnomad4 AFR
AF:
AC:
0.212849
AN:
0.212849
Gnomad4 AMR
AF:
AC:
0.123576
AN:
0.123576
Gnomad4 ASJ
AF:
AC:
0.166282
AN:
0.166282
Gnomad4 EAS
AF:
AC:
0.200078
AN:
0.200078
Gnomad4 SAS
AF:
AC:
0.301167
AN:
0.301167
Gnomad4 FIN
AF:
AC:
0.165177
AN:
0.165177
Gnomad4 NFE
AF:
AC:
0.153598
AN:
0.153598
Gnomad4 OTH
AF:
AC:
0.183886
AN:
0.183886
Heterozygous variant carriers
0
1142
2283
3425
4566
5708
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Genome Het
Genome Hom
Variant carriers
0
290
580
870
1160
1450
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
867
AN:
3442
ClinVar
Significance: Benign
Submissions summary: Benign:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Jul 05, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
not specified Benign:1
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Mucopolysaccharidosis, MPS-I-H/S Benign:1
Jul 10, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Mucopolysaccharidosis, MPS-I-S Benign:1
Jul 10, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Mucopolysaccharidosis type 1 Benign:1
Apr 13, 2018
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing
- -
Hurler syndrome Benign:1
Jul 10, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
Mutation Taster
=100/0
polymorphism (auto)
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at